Sumary of WHO advises doctors not to use Gilead’s remdesivir for COVID-19:
- The recommendation is a blow to Gilead drug, which was one of the first thought to offer a meaningful benefit in treatment of coronavirus patients after a study showed it reduced their recovery time..
- The experts made the recommendation after the results of a global trial sponsored by the WHO, called Solidarity, found last month that remdesivir didn’t reduce deaths..
- Food and Drug Administration approved the drug a week later, basing its decision on a trial run by the National Institutes of Health that showed remdesivir reduced hospitalized patients’ recovery time by five days..
- Multiple studies published in peer-reviewed journals have show remdesivir, also known by its brand name, Veklury, is beneficial against the virus, particularly in improving recovery time, “which can free up limited hospital resources,”.
- Despite the discordance with the WHO, the FDA said in its review of remdesivir that “there were no issues identified that would benefit from discussion”…